Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Donovan

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Pediatrics|October 3, 2002
The contribution of prone sleeping position to the racial disparity in sudden infant death syndrome: the Chicago Infant Mortality StudyFern R Hauck, Cathryn Merrick Moore, Stanislaw M Herman, et al.
European Journal of Heart Failure|February 19, 2008
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trialJohn J V McMurray, Peter E Carson, Michel Komajda, et al.
The New England Journal of Medicine|November 13, 2008
Irbesartan in patients with heart failure and preserved ejection fractionBarry M Massie, Peter E Carson, John J McMurray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Experimental Dermatology|March 3, 2012
Proteomic analysis identifies new biomarkers for postmenopausal and dry skinCaroline Delattre, Eric Winstall, Christian Lessard, et al.
The Lancet. Haematology|November 19, 2023
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trialSarah H O'Brien, Vilmarie Rodriguez, Glen Lew, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 29, 2022
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke PreventionMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
Circulation. Heart Failure|March 31, 2017
Reassessing Phase II Heart Failure Clinical Trials: Consensus RecommendationsJaved Butler, Carine E Hamo, James E Udelson, et al.
The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Pediatrics|October 3, 2002
The contribution of prone sleeping position to the racial disparity in sudden infant death syndrome: the Chicago Infant Mortality StudyFern R Hauck, Cathryn Merrick Moore, Stanislaw M Herman, et al.
European Journal of Heart Failure|February 19, 2008
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trialJohn J V McMurray, Peter E Carson, Michel Komajda, et al.
The New England Journal of Medicine|November 13, 2008
Irbesartan in patients with heart failure and preserved ejection fractionBarry M Massie, Peter E Carson, John J McMurray, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Experimental Dermatology|March 3, 2012
Proteomic analysis identifies new biomarkers for postmenopausal and dry skinCaroline Delattre, Eric Winstall, Christian Lessard, et al.
The Lancet. Haematology|November 19, 2023
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trialSarah H O'Brien, Vilmarie Rodriguez, Glen Lew, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|August 29, 2022
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke PreventionMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
Circulation. Heart Failure|March 31, 2017
Reassessing Phase II Heart Failure Clinical Trials: Consensus RecommendationsJaved Butler, Carine E Hamo, James E Udelson, et al.
The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
Pageof 4